Food and Drug Administration (FDA) has now approved two oral GLP-1 drugs: an oral version of Novo Nordisks Wegovy at the end of 2025, and Eli Lillys daily, non-peptide pillorforglipron, a distinct competitor to oral semaglutide and different from Eli Lillys injectable tirzepatidecalled Foundayo in April, which is notable because it can be taken without restrictions on timing or food or water intake
Most individuals at suicidal risk have some mental disorder
The third error is recommending that patients "round to the nearest unit" when a calculated dose falls between markings (for example, 12.5 units when the syringe only has 1-unit increments)
They can also offer nutritional support that focuses on your needs and provide lifestyle guidance to help you incorporate exercise, improve sleep, and manage stress
Most problems (infections, reduced potency, unexpected reactions) come from poor technique or improper storage, not from the peptides themselves
What safety risks exist with compounded semaglutide